

# ABOUT ALK+ ANAPLASTIC LYMPHOMA KINASE

## NON-SMALL CELL LUNG CANCER (NSCLC)



### LUNG CANCER

#### IT CAN AFFECT ANYONE.


Many people with lung cancer are former smokers or have never smoked.<sup>1,2</sup>



Worldwide, lung cancer **CAUSES MORE DEATHS** than colon, breast and prostate cancer combined.<sup>3</sup>

Each year, there are **1.6 MILLION PEOPLE** diagnosed with lung cancer worldwide.<sup>3</sup>


Estimated Number of Cancer Deaths Worldwide<sup>3</sup>



### TYPES OF LUNG CANCER


Lung cancers can be divided into different subsets in **TWO WAYS**:

**1 HISTOLOGY**  
The way the cells look under the microscope.<sup>2</sup>



**BIOMARKERS**  
Underlying genetic changes that drive cancer.


Within adenocarcinoma, there are different types based on unique genetic mutations and alterations.



### ALK+ NSCLC



**ABOUT 72,000 NSCLC PATIENTS** worldwide have ALK+ tumors.<sup>2,3</sup>



In ALK+ NSCLC, distinct portions of two genes, EML4 and ALK, can alternate and become fused together, creating an ALK “fusion protein” that promotes the growth of certain tumors.<sup>8</sup>

All lung cancer patients with adenocarcinoma should have their tumors tested for ALK. According to recent medical guidelines, **ALK & EGFR TESTING SHOULD BE PRIORITIZED** over other biomarkers.<sup>9</sup>



### DISEASE PROGRESSION

Personalized medicine has changed lung cancer. The discovery of new biomarkers and therapies has brought new treatment options to patients, **BUT PROGRESSION OCCURS**.<sup>4</sup>

**6 SIGNS** of cancer progression may include:<sup>2</sup>

- + Coughing
- + Pain
- + Fatigue
- + Dyspnea (difficulty breathing)
- + Loss of appetite & weight loss
- + Hemoptysis (spitting up blood)

Patients should be monitored regularly for symptoms of progression.

## NOVARTIS IS COMMITTED

## TO MAKING MEANINGFUL IMPROVEMENTS IN THE LIVES OF PATIENTS WITH ALK+ LUNG CANCER

For more information, visit [www.NovartisOncology.com](http://www.NovartisOncology.com)

1. Centers for Disease Control and Prevention. Cigarette Smoking Among Adults - United States, 2006. Morbidity and Mortality Weekly Report. Centers for Disease Control and Prevention. <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5644a2.htm>. Accessed on January 30, 2014.  
 2. American Cancer Society. Detailed Guide: Lung Cancer (Non-Small Cell) 2013. American Cancer Society. <http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf.pdf>. Accessed on January 30, 2014.  
 3. Jemal A, et al. Global cancer statistics. *CA Cancer J Clin*. 2011;61:69-90.  
 4. Riess JW, Wakelee HA. Metastatic Non-Small Cell Lung Cancer Management: Novel Targets and Recent Clinical Advances. *Clinical Advances in Hematology & Oncology*. 2012; 10: 226-224.  
 5. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. *Lancet Oncol*. 2011;12:175-180.  
 6. Paik PK, Arcila ME, Fara M, et al. Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations. *J Clin Oncol*. 2011;29:2046-2051.  
 7. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. *Nature*. 2012;378-381.  
 8. Lin E, Li L, Guan Y, et al. Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers. *Mol Cancer Res*. 2009;7(9):1466-1476.  
 9. Lindeman NI, Cagle PT, et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. *Arch Pathol Lab Med*. 2013; 137: 828-1174.  
 10. Camidge DR, Bang Y-J, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. *Lancet Oncol*. 2012;13(10):1011-1019.